Lighthouse Pharma Direct Investment Page

Lighthouse Pharma leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. The team has a decade of data informing their strategy, including patient responder analyses, rigorous dose modeling, and clinical execution.

Portfolio Company | In the News

Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease

May 10, 2023

Lighthouse announces FDA approval to proceed with Phase 2 SPRING Trial of LHP588, a next-generation treatment in development for Alzheimer's disease

November 16, 2023

Fund Performance Overview

Quarterly Reports

The highlights of Q3 2024 updates as provided by the company. Please note all updates provided are confidential and not for distribution. To access the file, use password: Q324LighthouseSPV!

ACCESS THE REPORT